Sean Kendall - Profile and Investment Details

Investor Profile

Sean Kendall is a Venture Capital, Investor, Private Equity Firm based in London, England, United Kingdom with a diverse investment portfolio that includes companies such as KSQ Therapeutics, OncoResponse, Remix Therapeutics, LifeMine Therapeutics, Cero Therapeutics, Encoded Therapeutics, Locanabio, Faraday Pharmaceuticals, AgBiome, Metacrine, One BioMed, Hangzhou Just Biotherapeutics (Just China), Biopalette, Karuna Therapeutics, Homology Medicines, Sana Biotechnology, Nebula Genomics, Nohla Therapeutics, Hua Medicine, Vividion Therapeutics, ImmuneID, Epirium Bio, Singleron Biotechnologies, Ultivue, Verve Therapeutics, Geneception, Aspen Neuroscience, Bit Bio, Erasca, Codiak Biosciences, Semma Therapeutics, UNITY Biotechnology, AnchorDx, Encodia, Sesh, EGenesis, Transcenta, Omniome, Maze Therapeutics, Resilience, ROME Therapeutics, Walden Biosciences, Sonoma BioTherapeutics, Vir Biotechnology, BlackThorn Therapeutics, Glympse Bio, Scholar Rock, Dewpoint Therapeutics, Volastra Therapeutics, Agrivida, ImmusanT, EQRx, Vizgen, Magnolia NeuroSciences, HiberCell, Gossamer Bio, Insitro, LunaPBC, Autobahn Therapeutics, CStone Pharmaceuticals, Nutcracker Therapeutics, Mindstrong, Boundless Bio, LunaDNA, Brii Biosciences, Beam Therapeutics, Voxel8, Cytrellis Biosystems, Qihan Biotech. Over time, Sean Kendall has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Sean Kendall is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Medical Testing, Enterprise Software, Life Science, Information Technology (IT), Biotech, EnergyTech, Software, Healthcare, Biotechnology, Hardware, Health Diagnostics, Chemicals, Medical, Semiconductors, Therapeutics, Media and Entertainment, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Sean Kendall, as their portfolio suggests a familiarity and interest in this area.

Understanding Sean Kendall’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.